Alpha-9 Oncology
Stephen Mitchener is an experienced executive in the oncology and biopharmaceutical sectors, currently serving as the Chief Business Officer at Alpha-9 Oncology. Previously, Mitchener held notable positions including Senior Vice President and Chief Business Officer at Karyopharm Therapeutics Inc. and Axcella, where responsibilities included strategic finance oversight. Additionally, Mitchener has experience as a Board Observer at Cota Healthcare and held several key roles at Novartis Oncology, including Head of US Oncology Strategy and Partnering & Operations. Academically, Mitchener holds a PharmD in Pharmacy from the University of North Carolina at Chapel Hill and attended Rutgers University for advanced studies from 2003 to 2005.
Alpha-9 Oncology
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.